|
gptkbp:instanceOf
|
antidiabetic medication
long-acting insulin
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:Japan
gptkb:FDA
2015
|
|
gptkbp:ATCCode
|
A10AE06
|
|
gptkbp:brand
|
gptkb:Tresiba
|
|
gptkbp:CASNumber
|
844439-96-9
|
|
gptkbp:chemicalClass
|
gptkb:insulin
|
|
gptkbp:developedBy
|
gptkb:Novo_Nordisk
|
|
gptkbp:duration
|
over 42 hours
|
|
gptkbp:eliminationHalfLife
|
25 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:halfLife
|
25 hours
|
|
gptkbp:hasMolecularFormula
|
C274H411N65O81S6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Insulin degludec
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
insulin receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
low
|
|
gptkbp:riskFactor
|
gptkb:hypoglycemia
weight gain
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
gptkb:hypoglycemia
allergic reactions
injection site reactions
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes
type 1 diabetes
|
|
gptkbp:bfsParent
|
gptkb:insulin
|
|
gptkbp:bfsLayer
|
6
|